Abstract 4632
Background
Adjuvant dose-dense chemotherapy improves breast cancer (BC) outcomes compared to standard chemotherapy, with no increase in chemotherapy-induced amenorrhea (CIA). However, the impact of menopausal status and the contribution of CIA to outcomes per subtype remain unclear.
Methods
PANTHER is a phase 3 trial comparing tailored, according to hematologic nadirs, and dose-dense (tdd) epirubicin/cyclophosphamide (EC) and docetaxel (D) versus standard interval FEC/D. The primary endpoint of the trial is relapse-free survival (BCRFS). This exploratory secondary analysis aimed to evaluate whether there was differential efficacy of tdd therapy according to menopausal status and if differences in CIA, defined as amenorrhea at 2 years following treatment, may contribute to its efficacy.
Results
Baseline menopause status was available for 1913 women; 1036 premenopausal and 877 postmenopausal. Median follow-up was 5.3 years. The administration of tdd EC/D was associated with a non-statistically significant improvement in BCRFS in both premenopausal (HR = 0.83, 95% CI 0.59 – 1.16, p = 0.265) and postmenopausal patients (HR = 0.74, 95% CI 0.51 – 1.06, p = 0.102; pinteraction0.658). On the contrary, a significant interaction was noticed in women with triple negative BC (TNBC, p = 0.043). Tdd EC/D improved BCRFS in postmenopausal women (HR = 0.44, 95% CI 0.19 – 1.03, p = 0.06) but had a trend to opposite effect among premenopausal women (HR = 1.29, 95% CI 0.69 – 2.40, p = 0.426). There was no difference in CIA rates between the two treatment groups (OR = 1.04, 95% CI 0.77 – 1.39).
Conclusions
Tdd EC/D was associated with non-significant improvements in BCRFS, regardless of menopause status, without increasing rates of CIA. Negative effect on TNBC could be a chance finding due to low number of patients but the results warrant caution and necessitate further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swedish Cancer Society, Swedish Breast Cancer Association (BRO), Radiumhemmet Research funds, Amgen, Roche, Sanofi-Aventis.
Disclosure
G. Steger: Honoraria (self): Amgen. R. Greil: Honoraria (self): Amgen; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self): MSD; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self): BMS; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Janssen; Research grant / Funding (self): Roche; Research grant / Funding (self): BMS; Research grant / Funding (self): AstraZeneca. S. Loibl: Research grant / Funding (institution): Vigor; Honoraria (institution): AstraZeneca; Honoraria (institution): Amgen; Honoraria (institution): Pfizer; Honoraria (institution): Roche; Honoraria (institution): Puma; Honoraria (institution): Novartis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Amgen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Puma; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Celgene; Travel / Accommodation / Expenses: Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Teva. M. Gnant: Honoraria (self), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self): Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Honoraria (self): Invectys; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Nano string; Honoraria (self): Novartis; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): Medison; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Medison. V. Moebus: Honoraria (self): Amgen; Honoraria (self): Celgene; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Myelotherapeutics; Honoraria (self): AstraZeneca. T. Foukakis: Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Novartis; Honoraria (self): UptoDate. J. Bergh: Research grant / Funding (institution): Merck; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi-Aventis; Honoraria (self): Uptodate. All other authors have declared no conflicts of interest.
Resources from the same session
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract
2376 - Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease
Presenter: Johannes Ettl
Session: Poster Display session 2
Resources:
Abstract